Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C4H9N3O2.H2O |
| Molecular Weight | 149.1484 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.CN(CC(O)=O)C(N)=N
InChI
InChIKey=MEJYXFHCRXAUIL-UHFFFAOYSA-N
InChI=1S/C4H9N3O2.H2O/c1-7(4(5)6)2-3(8)9;/h2H2,1H3,(H3,5,6)(H,8,9);1H2
| Molecular Formula | C4H9N3O2 |
| Molecular Weight | 131.1332 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Creatine is an amino acid that occurs in vertebrate tissues and in urine. It is synthesized mainly in the liver from three different amino acids: arginine, glycine, and methionine. In skeletal muscles, which store 95% of it, creatine generally occurs as phosphocreatine. The rest is stored in the brain, heart, and testes. Creatine functions as part of the cell's energy shuttle. It is excreted as creatinine in the urine.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. | 2001-04 |
|
| Assessment of coronary reperfusion in patients with myocardial infarction using fatty acid binding protein concentrations in plasma. | 2001-03 |
|
| IGF-I differentially regulates Bcl-xL and Bax and confers myocardial protection in the rat heart. | 2001-03 |
|
| An (1)H-MRS evaluation of the phosphocreatine/creatine pool (tCr) in human muscle. | 2001-03 |
|
| Mechanical load increases muscle IGF-I and androgen receptor mRNA concentrations in humans. | 2001-03 |
|
| Creatine transporter protein content, localization, and gene expression in rat skeletal muscle. | 2001-03 |
|
| Use of ergogenic aids by athletes. | 2001-02-15 |
|
| Dysarthria as the leading symptom of hypothyroidism. | 2001-02-15 |
|
| Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. | 2001-02-08 |
|
| Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control. | 2001-02-01 |
|
| Mouse model of myocardial remodelling after ischemia: role of intercellular adhesion molecule-1. | 2001-02-01 |
|
| Neuroprotective effects of MK-801 on L-2-chloropropionic acid-induced neurotoxicity. | 2001-02 |
|
| Phosphorylation-dependent alteration in myofilament ca2+ sensitivity but normal mitochondrial function in septic heart. | 2001-02 |
|
| Parkinsonism and neck extensor myopathy: a new syndrome or coincidental findings? | 2001-02 |
|
| Thrombectomy with the X-SIZER catheter system in the coronary circulation: initial results from a multi-center study. | 2001-02 |
|
| Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. | 2001-02 |
|
| A controlled trial of topical nitroglycerin in a New Zealand white rabbit model of brown recluse spider envenomation. | 2001-02 |
|
| The three-dimensional structure of cytosolic bovine retinal creatine kinase. | 2001-02 |
|
| Tubular cell senescence and expression of TGF-beta1 and p21(WAF1/CIP1) in tubulointerstitial fibrosis of aging rats. | 2001-02 |
|
| Protection against cellular damage in the rat heart by iodoacetate. | 2001-02 |
|
| Release of muscle proteins after downhill running in male and female subjects. | 2001-02 |
|
| Serum concentrations of collagen degrading enzymes and their inhibitors after downhill running. | 2001-02 |
|
| Uremic concentrations of guanidino compounds inhibit neutrophil superoxide production. | 2001-02 |
|
| Cardiac troponins and creatine kinase content of striated muscle in common laboratory animals. | 2001-02 |
|
| Altered activities of rat brain metabolic enzymes caused by pentylenetetrazol kindling and pentylenetetrazol--induced seizures. | 2001-02 |
|
| Endogenous synthesis and transport of creatine in the rat brain: an in situ hybridization study. | 2001-01-31 |
|
| Expression and purification of polyhistidine-tagged firefly luciferase in insect cells--a potential alternative for process scale-up. | 2001-01-23 |
|
| Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. | 2001-01-20 |
|
| Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. | 2001-01-06 |
|
| Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems. | 2001-01-05 |
|
| Deterioration in renal function associated with fibrate therapy. | 2001-01 |
|
| Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. | 2001-01 |
|
| Exercise training increases creatine kinase capacity in canine myocardium. | 2001-01 |
|
| Creatine supplementation affects muscle creatine during energy restriction. | 2001-01 |
|
| Treatment of exercise-induced muscle injury via hyperbaric oxygen therapy. | 2001-01 |
|
| Effect of elbow joint angle on the magnitude of muscle damage to the elbow flexors. | 2001-01 |
|
| Oxygen free radical generation in healthy blood donors and cardiac patients: the protective effect of allopurinol. | 2001-01 |
|
| Leukocyte filtration in the early reperfusion phase on cardiopulmonary bypass reduces myocardial injury. | 2001-01 |
|
| Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. | 2001-01 |
|
| Clinical, electrocardiographic, and biochemical data for immediate risk stratification in acute coronary syndromes. | 2001-01 |
|
| Improving diagnostic yield in brain biopsy: coupling spectroscopic targeting with real-time needle placement. | 2001-01 |
|
| Plasma lipids and urinary albumin excretion rate in Type 1 diabetes mellitus: the EURODIAB IDDM Complications Study. | 2001-01 |
|
| Systemic effects of hyperthermic isolated lower limb perfusion with carboplatin and interferon-beta. | 2001-01 |
|
| Evaluation of the dystrophin-glycoprotein complex, alpha-actinin, dysferlin and calpain 3 in an autosomal recessive muscular dystrophy in Labrador retrievers. | 2001-01 |
|
| Mild phenotype of nemaline myopathy with sleep hypoventilation due to a mutation in the skeletal muscle alpha-actin (ACTA1) gene. | 2001-01 |
|
| Effects of EGF receptor ligands on fetal ovine myoblasts. | 2001-01 |
|
| Alterations in myocardial creatinine kinase (CK) and lactate dehydrogenase (LDH) isoenzyme-distribution in a model of left ventricular dysfunction. | 2001-01 |
|
| Pretreatment of human myocardium with adenosine. | 2001-01 |
|
| Validation of NACB and IFCC guidelines for the use of cardiac markers for early diagnosis and risk assessment in patients with acute coronary syndromes. | 2001-01 |
|
| Evolution and physiological roles of phosphagen systems. | 2001 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:16:44 GMT 2025
by
admin
on
Mon Mar 31 19:16:44 GMT 2025
|
| Record UNII |
9603LN7R2Q
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
298309
Created by
admin on Mon Mar 31 19:16:44 GMT 2025 , Edited by admin on Mon Mar 31 19:16:44 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Creatine monohydrate
Created by
admin on Mon Mar 31 19:16:44 GMT 2025 , Edited by admin on Mon Mar 31 19:16:44 GMT 2025
|
PRIMARY | |||
|
931
Created by
admin on Mon Mar 31 19:16:44 GMT 2025 , Edited by admin on Mon Mar 31 19:16:44 GMT 2025
|
PRIMARY | |||
|
C1505
Created by
admin on Mon Mar 31 19:16:44 GMT 2025 , Edited by admin on Mon Mar 31 19:16:44 GMT 2025
|
CONCEPT | Dietary Supplement | ||
|
1310467
Created by
admin on Mon Mar 31 19:16:44 GMT 2025 , Edited by admin on Mon Mar 31 19:16:44 GMT 2025
|
PRIMARY | RxNorm | ||
|
9603LN7R2Q
Created by
admin on Mon Mar 31 19:16:44 GMT 2025 , Edited by admin on Mon Mar 31 19:16:44 GMT 2025
|
PRIMARY | |||
|
9603LN7R2Q
Created by
admin on Mon Mar 31 19:16:44 GMT 2025 , Edited by admin on Mon Mar 31 19:16:44 GMT 2025
|
PRIMARY | |||
|
80116
Created by
admin on Mon Mar 31 19:16:44 GMT 2025 , Edited by admin on Mon Mar 31 19:16:44 GMT 2025
|
PRIMARY | |||
|
DTXSID10208954
Created by
admin on Mon Mar 31 19:16:44 GMT 2025 , Edited by admin on Mon Mar 31 19:16:44 GMT 2025
|
PRIMARY | |||
|
SUB22738
Created by
admin on Mon Mar 31 19:16:44 GMT 2025 , Edited by admin on Mon Mar 31 19:16:44 GMT 2025
|
PRIMARY | |||
|
C28945
Created by
admin on Mon Mar 31 19:16:44 GMT 2025 , Edited by admin on Mon Mar 31 19:16:44 GMT 2025
|
PRIMARY | |||
|
6020-87-7
Created by
admin on Mon Mar 31 19:16:44 GMT 2025 , Edited by admin on Mon Mar 31 19:16:44 GMT 2025
|
PRIMARY | |||
|
100000086558
Created by
admin on Mon Mar 31 19:16:44 GMT 2025 , Edited by admin on Mon Mar 31 19:16:44 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |